Margarida Serra’s team from the Instituto de Biologia Experimental e Tecnológica has potentially improved the development of liver disease treatments by controlling the oxygen levels in bioreactors to produce more hepatocyte-like cells (HLCs). Current methods generate low numbers of HLCs, but the research found that reducing oxygen levels to 4% boosts number and differentiation of HLCs, setting the stage for future liver disease treatments.
The True Cost of Focusing on Cost Instead of Cost-Effectiveness
When payors consider only the cost of the medication and not the cost and risk to the patient, doctor, and healthcare system, the irony is
